Research progress of redifferentiation of radioiodine-refractory differentiated thyroid carcinoma
10.3760/cma.j.issn.2095-2848.2017.09.014
- VernacularTitle:131I难治性分化型甲状腺癌再分化的研究进展
- Author:
Liangliang BAI
;
Bingyu RAO
;
Jichun YU
;
Wanzhi CHEN
- Keywords:
Thyroid neoplasms;
Radiotherapy;
Iodine radioisotopes;
Treatment failure;
Redifferentiation;
Trends
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2017;37(9):579-583
- CountryChina
- Language:Chinese
-
Abstract:
The effect of 131I therapy for primary and metastatic lesions of thyroid carcinoma depends on the ability of iodine uptake.The loss or down-regulation of iodine-metabolizing genes represents dedifferentiation of DTC,which results in the disability to take up and accumulate 131I and eventually leads to radioiodine-refractory DTC (RR-DTC).The management of RR-DTC is extremely difficult and the prognosis is poor.It is important for the treatment and prognosis of RR-DTC to investigate the mechanism of redifferentiation.The up-regulation of thyroid iodine-metabolizing genes expression,inhibition of the changes in epigenetic modifications and intervention of the abnormal activation of signaling pathways are reviewed in this article.
